REG - ValiRx PLC - ValiRx and TwinEdge to present Digital Twin data

ValiRxAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260324:nRSX7660Xa&default-theme=true

RNS Number : 7660X  ValiRx PLC  24 March 2026

24 March 2026

 

ValiRx PLC

("ValiRx" or the "Company")

 

ValiRx and TwinEdge to present Digital Twin data

 

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on
early-stage cancer therapeutics and women's health is pleased to announce that
TwinEdge Bioscience ("TwinEdge"), ValiRx Plc ("ValiRx") and its wholly owned
subsidiary Inaphaea Biolabs Ltd ("Inaphaea"), will present an abstract at the
American Association of Cancer Research in San Diego on 22 April 2026. The
abstract, number 8679/23, titled "Integrating omics-driven digital avatars
with patient-derived experimental models to accelerate precision oncology"
will be published in an online-only supplement to the AACR journal Cancer
Research on Friday, 3 April 2026.

The abstract, jointly authored by TwinEdge, ValiRx and Inaphaea describes the
work to establish a framework for predicting, testing, and refining
precision-treatment strategies, integrating (i) data profiling of ValiRx's
patient-derived cancer models, and (ii) construction of Digital Avatars using
TwinEdge's modelling engine. Further details can be found online at
https://www.abstractsonline.com/pp8/#!/21436/presentation/3310
(https://www.abstractsonline.com/pp8/#!/21436/presentation/3310) . This is the
first peer reviewed publication of the Company's PDC digitisation approach
with TwinEdge.

Inaphaea was also recently invited to submit an editorial article in the Drug
Discovery World Spring 2026 edition. The article, titled "Rewriting the
Oncology Playbook", discusses how patient derived models can bridge the
translational divide in oncology. The full article, published online, can be
found at https://online.flippingbook.com/view/366735074/22/
(https://online.flippingbook.com/view/366735074/22/) .

ValiRx has also co-authored an article titled "EZH2 inhibition enhances the
activity of Carboplatin in aggressive-variant prostate cancer cell lines" in
the peer reviewed journal Epigenomics with collaborators at the Open
University, the University of Cambridge, Belgium Volition, the University of
Basel, the Istituto Nazionale dei Tumori, Nagoya University, Lancaster
University and the University of British Columbia. The article discusses how
the activity of a standard of care drug, Carboplatin, can be enhanced with
other treatment modalities for the treatment of aggressive prostate cancer.
The full article can be found online at
https://doi.org/10.1080/17501911.2025.2453419
(https://doi.org/10.1080/17501911.2025.2453419) .

ValiRx CEO, Dr Mark Eccleston has presented data on the potential host immune
activating properties of its oncolytic peptide formulations and sat on expert
panels at three recent conferences including the opening keynote presentation
"Oncolytic Peptides - Turning Cold Tumors Hot" at the 6(th) ACE Drug discovery
summit, "OncoLytic Peptides - A novel Initiator of Immunogenic Cell Death for
Immune Cell Recruitment" at the ImmunoMark Summit and "Reprogramming the
Tumour microenvironment with a novel oncolytic peptide" at the Immuno-Oncology
& Biomarker Summit 2026.

Dr Eccleston will also be sitting on another expert panel discussing "Life Of
A Peptide & Cross Modalities" at the Next Gen Biomed conference on 24
March 2026 alongside Hannah Bolt, Head of Peptide Discovery, Director,
AstraZeneca, Alastair Hay, Vice President, Almac and Anders Dahlen, Senior
Director, AstraZeneca chaired by Charles Johannes, co-founder & President
of the Peptide Drug Hunding Consortium.

Mark Eccleston, CEO of ValiRx commented "It's great to see the peer reviewed
articles we're submitting with our various collaborators being accepted whilst
also being invited to submit op-ed pieces to trade journals, present at
leading industry conferences and sit on expert panels. This really shows that
the work we're doing is timely and relevant, which is particularly true of our
NAMs platforms and the immune-oncology applications for our oncolytic peptide
programme. Having the opportunity to showcase our work in front of industry
leaders in this way is vital to our partnering strategy. In particular, The
AACR Annual Meeting is the focal point of the cancer research community, where
scientists, clinicians, other health care professionals, survivors, patients,
and advocates gather to share the latest advances in cancer science and
medicine. The meeting will be well attended by all the major pharma companies
providing a great platform to update the leading industry players on our
various programmes. The relationship with TwinEdge has been extremely
fruitful."

The Directors of the Company are responsible for the release of this
announcement.

 

*** ENDS ***

Engage with the ValiRx management team directly by asking questions, watching
video
summaries and seeing what other shareholders have to say. Navigate to
our Interactive Investor
hub here: https://valirx.com/s/cc8ef3

For more information, please contact:

 

 Investor questions on this announcement           https://valirx.com/link/yMQK4y (https://valirx.com/link/yMQK4y)

 We encourage all investors to share questions

 on this announcement via our investor hub
 ValiRx plc                                        Tel: +44 115 784 0026

                                                   www.valirx.com (http://www.valirx.com)

 Dr Mark Eccleston, CEO                            Mark.Eccleston@valirx.com

 Cairn Financial Advisers LLP (Nominated Adviser)  Tel: +44 (0) 20 7213 0880

 Liam Murray / Ludovico Lazzaretti

 Shard Capital Partners LLP (Sole Broker)          Tel: +44 (0) 20 7186 9000

 Damon Heath

 V Formation (Public Relations)                    +44 (0) 115 787 0206

                                                   www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                               lucy@vformation.biz

                                                   sue@vformation.biz

 

Subscribe to our news alert service: https://valirx.com/s/f298d1
(https://valirx.com/s/f298d1)

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPPUUWWUPQGMW



            Copyright 2019 Regulatory News Service, all rights reserved